Clinical Chemistry AACC Online Job Center
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 31: 1468-1473, 1985;
This Article
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Schifreen, R. S.
Right arrow Articles by Waller, S. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schifreen, R. S.
Right arrow Articles by Waller, S. J.

Clinical Chemistry, Vol 31, 1468-1473, Copyright © 1985 by American Association for Clinical Chemistry

A quantitative automated immunoassay for fibrinogen/fibrin degradation products

RS Schifreen, GS Cembrowski, DC Campbell, AR Craig, ND Demyanovich, PA Jurga- Hall, MC Reider, MW Schwartz, PM Tuhy and SJ Waller

We describe a prototype quantitative automated assay for fibrin and fibrinogen degradation products, a particle-enhanced turbidimetric inhibition immunoassay (PETINIA) in the Du Pont aca discrete clinical analyzer. This assay involves a latex particle reagent with covalently bound fibrinogen and a polyclonal antiserum raised in rabbits against human fibrinogen. A special secondary sample-collection tube quantitatively removes fibrinogen from citrated plasma and inhibits further fibrinolysis, independent of heparin concentration. The assay range is 0-100 mg/L, in fibrinogen equivalents. The CV for the assay is less than 10% when performed with the aca. Nonclottable fibrin and fibrinogen fragments are measured by the assay, the greatest sensitivity being directed at the E domain of the fibrinogen molecule. We illustrate with case studies the potential of this assay for providing clinical information not obtainable with currently available qualitative and semi-quantitative assays.


The following articles in journals at HighWire Press have cited this article:


Home page
 Clin. Chem.Home page
H. Thakkar, D. J. Newman, P. Holownia, C. L. Davey, C.-C. Wang, J. Lloyd, A. R. Craig, and C. P. Price
Development and validation of a particle-enhanced turbidimetric inhibition assay for urine albumin on the Dade aca(R) analyzer
Clin. Chem., January 1, 1997; 43(1): 109 - 113.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1985 by the American Association for Clinical Chemistry.